https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(MedPage Today) — DENVER — Treatment-resistant dermatomyositis improved significantly with the investigational TYK2/JAK1 inhibitor brepocitinib, according to a randomized trial.
The higher of two doses of brepocitinib improved the total dermatomyositis…
:max_bytes(150000):strip_icc()/Health-GettyImages-2165665322-f21ef5a24b084ac3a6b6c95d260e7a53.jpg?w=390&resize=390,220&ssl=1 "How Much Coffee Is Too Much? Here’s What the Science Says")
